Amikacin
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
Doxacurium
Neuromuscular Blocker
Neuromuscular Blocker
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
11 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 11 →
- AmikacinSevereDatabaseDDInter
- Botulinum Toxin Type ASevereDatabaseDDInter
- Botulinum Toxin Type BSevereDatabaseDDInter
- ColistimethateSevereDatabaseDDInter
Mechanism
Doxacurium is a nondepolarizing (competitive) neuromuscular blocking agent. It acts at the end plate of skeletal muscle fibers where it competitively blocks acetylcholine receptors, thereby inhibiting neuromuscular transmission and causing muscle relaxation. It is noted for being more selective in terms of not causing significant ganglionic blockade compared to older agents.
Indications
To provide muscle relaxation for surgeryAdjuvant in surgical anesthesia to obtain relaxation of skeletal muscleLong duration surgeries
Dosing
- Adult
- 0.03–0.06 mg/kg (initiation)
Pharmacokinetics
Onset
Rapid onset with intravenous administration
Duration
Long acting
Bioavailability
Very poorly absorbed from the GI tract; adequate absorption from intramuscular sites; rapid onset with intravenous administration
Excretion
Renal elimination
Side effects
Serious
- Less ganglionic blockade
Drug interactions
Botulinum Toxin Type A
Severe
Database
Clinical effect not specified
Source: DDInter
Botulinum Toxin Type B
Severe
Database
Clinical effect not specified
Source: DDInter
Colistimethate
Severe
Database
Clinical effect not specified
Source: DDInter
Kanamycin
Severe
Database
Clinical effect not specified
Source: DDInter
Netilmicin
Severe
Database
Clinical effect not specified
Source: DDInter
Paromomycin
Severe
Database
Clinical effect not specified
Source: DDInter
Plazomicin
Severe
Database
Clinical effect not specified
Source: DDInter
Polymyxin B
Severe
Database
Clinical effect not specified
Source: DDInter
Streptomycin
Severe
Database
Clinical effect not specified
Source: DDInter
Tobramycin
Severe
Database
Clinical effect not specified
Source: DDInter
1 additional low-confidence interaction hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Neuromuscular Blocker drugs
Ask House about Doxacurium
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team